The Healthcare and Science business of Thomson Reuters has released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.
Read more ...
Research paves way for life-threatening bacterial infection test
EU-funded researchers have demonstrated how a recently identified protein causes a simple bacterial infection to turn into a potentially fatal condition called rheumatic heart disease. The researchers are now using their newfound knowledge to develop a test system that will be able to identify the bacteria when the infection is still in its early stages.
Read more ...
New drug resistance threatens to deal blow to malaria control efforts worldwide
The World Health Organization (WHO) has expressed its concern over the emergence along the Thai-Cambodia border of malaria parasites that are resistant to a previously highly effective drug. WHO fears that the Plasmodium parasites' growing resistance to the drug artemisinin "could seriously undermine the success of global malaria control efforts".
Read more ...
A big leap for the small in fighting disease
Given the opportunity, small and medium-sized enterprises (SMEs) can play a key role in developing therapies for some of society's most common diseases. It was for this reason that the European Commission (EC) supported a team of European universities and SMEs with over EUR 2 million to pursue the aims set out by the MACROCEPT project, and its daughter project KINACEPT, to find a treatment for rheumatoid arthritis.
Read more ...
HIV in arms race with human immune system, study reveals
HIV (human immunodeficiency virus) is evolving rapidly to get round the weaponry of the human immune system, according to new research by an international team of scientists. The findings highlight the difficulty of developing an effective vaccine against the fast-evolving virus.
Read more ...
Biopharmaceutical Companies Risk Delays in Producing Targeted Treatment Solutions
A new survey released by IBM (NYSE: IBM) and Silico Research reveals that if biopharmaceutical - or life-sciences - companies fail to collaborate, they risk costly delays in the production of new medicines, medical devices, diagnostics and support services.
Read more ...
Heart attacks linked with antiretroviral treatment
New research has helped to explain why patients being treated with antiretroviral drugs for HIV experience a greater incidence of heart attacks. The research was presented by doctors and researchers from the School of Medicine and Medical Sciences at University College Dublin, the Mater Misericordiae University Hospital in Dublin and the Royal College of Surgeons in Ireland at the Retroviral Conference in Montreal, Canada, on 11 February.
Read more ...